New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO ® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
RARITAN, NJ, September 27, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO® (rivaroxaban) in an oral suspension formulation, compared to treatment with aspirin, was associated with numerically fewer blood clots and clinical events strongly associated with blood clots in pediatric patients (aged 2-8 years) who have undergone the Fontan procedure. [1] These findings, which were published this month in the Journal of the American Heart Association and included in a recent New Drug Application submitted to the...
Source: Johnson and Johnson - September 27, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Can Cannabis Help Your Gut?
When Joe Silverman developed Crohn’s disease at age 21, the symptoms started out mild. While the sight of blood in his stools initially freaked him out, what really bothered him was the frequent abdominal pain and bloating that occurred as his condition progressed to moderate and then severe. Dietary changes didn’t make a difference, so he began taking prescription oral anti-inflammatory drugs that are often used to treat certain bowel diseases, which alleviated but didn’t eliminate his discomfort. He started using prescription steroid suppositories to cope with flare-ups of the inflammatory bowel disease...
Source: TIME: Health - September 23, 2021 Category: Consumer Health News Authors: Stacey Colino Tags: Uncategorized Source Type: news

Renal Decline Slower With Rivaroxaban Than Warfarin in AF Patients Renal Decline Slower With Rivaroxaban Than Warfarin in AF Patients
The oral anticoagulant rivaroxaban is associated with both slower decline in kidney function and reduced risk of renal events compared with warfarin in atrial fibrillation patients.Medscape News UK (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 31, 2021 Category: Consumer Health News Tags: Cardiology News Source Type: news

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) e...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Rates of Adverse Events Lower With Apixaban for A - Fib in Older Adults
Apixaban the only direct oral anticoagulant linked to lower adverse event rates than warfarin for patients with atrial fibrillation across frailty levels (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 20, 2021 Category: Cancer & Oncology Tags: Cardiology, Internal Medicine, Oncology, Pharmacy, Geriatrics, Journal, Source Type: news

Rates of Adverse Events Lower With Apixaban for A-Fib in Older Adults
TUESDAY, July 20, 2021 -- For older adults with atrial fibrillation, apixaban is associated with lower rates of adverse events than warfarin across all frailty levels, according to a study published online July 20 in the Annals of Internal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 20, 2021 Category: Pharmaceuticals Source Type: news

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with co...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

No Benefit to Postop Heparin Bridging in Patients Who Stop Warfarin for a Procedure No Benefit to Postop Heparin Bridging in Patients Who Stop Warfarin for a Procedure
There does not appear to be a benefit to postoperative heparin bridging in patients with atrial fibrillation or a mechanical heart valve who temporarily stop taking warfarin before a planned procedure, according to results of the PERIOP2 study.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - June 18, 2021 Category: Surgery Tags: Cardiology News Source Type: news

Late-Breaking Data at ACC.21 Show XARELTO ® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization
RARITAN, N.J., May 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event. The primary results of VOYAGER PAD showed that XARELTO® plus aspirin reduced first events by 15 percent among patients...
Source: Johnson and Johnson - May 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Effectiveness of Anticoagulants Compared for Valvular A-Fib
TUESDAY, March 30, 2021 -- For patients who are new to therapy for valvular atrial fibrillation (AF), direct oral anticoagulants (DOACs) as a class are effective and safe compared with warfarin, with some variability among individual DOACs,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 30, 2021 Category: Pharmaceuticals Source Type: news

Unexpected severe intra-abdominal injuries resulting from a ground-level fall in an elderly patient with a large staghorn calculus - Lightfoot A, Chan J.
A 70-year-old woman on warfarin was transported to the emergency department after a ground-level fall, injuring her left backside. Criteria for geriatric trauma activation was not met. An episode of haematuria created suspicion for an intra-abdominal injur... (Source: SafetyLit)
Source: SafetyLit - March 25, 2021 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Aspirin preferred to prevent blood clots in kids after heart surgery
(Murdoch Childrens Research Institute) Aspirin should be favoured over warfarin to prevent blood clotting in children who undergo a surgery that replumbs their hearts, according to a new study. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 14, 2021 Category: International Medicine & Public Health Source Type: news

The effect of Covid-19 related lockdown on patients taking warfarin, Nottingham University Hospitals NHS Trust
This service improvement study looked at time periods pre-COVID-19, pre lockdown, lockdown and post lockdown, and noted time in therapeutic range during lockdown dropped. These data were used by service so that it was better prepared to manage patients during subsequent lockdown. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 6, 2021 Category: Consumer Health News Source Type: news

Comunicado de la FDA sobre la seguridad de los medicamentos: Actualizaci ón sobre el riesgo de eventos severos de hemorragia con el anticoagulante Pradaxa (dabigatrán etexilato mesilato)
[5 de noviembre del 2012. La Administraci ón de Alimentos y Medicamentos de Estados Unidos (FDA pos sus siglas en inglés) ha evaluado nueva información sobre hemorragias severas con el uso de los anticoagulantes dabigatrán (Pradaxa) y warfarina (Coumadin, Jantoven y medicamentos genéricos). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 4, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

ACR: Warfarin Tied to Increased Risk for Knee, Hip Replacement in OA
MONDAY, Nov. 16, 2020 -- For adults with atrial fibrillation, warfarin is associated with an increased risk for knee and hip replacements for osteoarthritis (OA), according to a study presented at ACR Convergence, the annual meeting of the American... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 16, 2020 Category: Pharmaceuticals Source Type: news

RIVER: Rivaroxaban Rivals Warfarin in AF, Mitral Bioprosthesis RIVER: Rivaroxaban Rivals Warfarin in AF, Mitral Bioprosthesis
The trial from Brazil may not be easily extrapolated to other regions, but it starts to fill a largely vacant evidence base for patients not well represented in major trials of nonvalvular AF DOACs.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 15, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need f...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Warfarin Use Linked to Knee and Hip Replacement in OA Patients Warfarin Use Linked to Knee and Hip Replacement in OA Patients
Patients who take vitamin K antagonist warfarin to prevent thromboembolic events are significantly more likely to require knee or hip replacement surgery than those who take direct oral anticoagulants.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 9, 2020 Category: Cardiology Tags: Rheumatology News Source Type: news

Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revasculariz...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Warfarin and other anticoagulants: monitoring of patients during the COVID-19 pandemic, MHRA
The MHRA has issued advice to healthcare professionals and patients regarding the safe use of warfarin and other anticoagulants, following concerns over an apparent increase in the number of patients taking warfarin found to have an elevated INR during the COVID-19 pandemic. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - October 26, 2020 Category: Consumer Health News Source Type: news

COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community [NG163], NICE (updated 13th October 2020)
MHRA advice on warfarin and other anticoagulants: In October 2020, we amended recommendations on taking into account a patient's existing medicines to link to 2 External 0 0 0 MHRA advice on warfarin and other anticoagulants – monitoring of patients during the COVID-19 pandemic false https://www.gov.uk/government/publications/warfarin-and-other-anticoagulants-monitoring-of-patients-during-the-covid-19-pandemic true false%>, which includes reports of supratherapeutic anticoagulation with warfarin. This guideline focuses on what you need to stop or start doing during the pandemic. Follow the usual professional guid...
Source: Current Awareness Service for Health (CASH) - October 15, 2020 Category: Consumer Health News Source Type: news

Warfarin and other anticoagulants monitoring of patients during the COVID-19 pandemic, MHRA
MHRA has published guidance following concerns over an apparent increase in the number of patients taking warfarin found to have elevated INR values during the pandemic; and reminds healthcare professionals and patients that continued close INR monitoring is crucial. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - October 15, 2020 Category: Consumer Health News Source Type: news

Warfarin and other anticoagulants – monitoring of patients during the COVID-19 pandemic
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued guidance on Warfarin and other anticoagulants– monitoring of patients during the COVID-19 pandemic. Further informatio (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - October 13, 2020 Category: Drugs & Pharmacology Source Type: news

Drugs to Avoid in Patients on DOACs Drugs to Avoid in Patients on DOACs
DOACs overall have substantially fewer drug-drug interactions than warfarin, but there are still a few to watch out for.Medscape Internal Medicine (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 23, 2020 Category: Cardiology Tags: Cardiology Clinical Case Source Type: news

DOACs Linked to Lower Fracture Risk vs Warfarin in AFib Patients DOACs Linked to Lower Fracture Risk vs Warfarin in AFib Patients
A recent population-based cohort study is one of the latest reports to suggest direct oral anticoagulants could have an edge over warfarin for preventing fractures.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - May 21, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Osteoporotic Fracture Risk Lower for DOAC Than Warfarin in A-Fib
MONDAY, May 18, 2020 -- For patients with atrial fibrillation (AF), the risk for osteoporotic fracture appears to be lower with direct oral anticoagulant (DOAC) use compared with warfarin use, according to a study published online May 19 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 18, 2020 Category: Pharmaceuticals Source Type: news

AMP recommends minimum set of pharmacogenetic alleles to help standardize clinical genotyping testing for warfarin response
(Association for Molecular Pathology) AMP has published consensus, evidence-based recommendations to aid in the design, validation and interpretation of clinical genotyping tests for the prediction of warfarin response. The manuscript, 'Recommendations for Clinical Warfarin Sensitivity Genotyping Allele Selection: A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists,' was released online ahead of publication in The Journal of Molecular Diagnostics. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 5, 2020 Category: International Medicine & Public Health Source Type: news

Costs in warfarin-sensitive versus warfarin-insensitive patients
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 30, 2020 Category: Drugs & Pharmacology Source Type: news

Cautions Raised Against Off-Label DOACs to Clear LV Thrombi Cautions Raised Against Off-Label DOACs to Clear LV Thrombi
Oral anticoagulation rules for left ventricular thrombus, but trial guidance is in short supply. Tempting as they may be for the indication, the newer agents may not protect as well as warfarin.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 29, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Vitamin K Antagonists and Osteoporotic Fractures Vitamin K Antagonists and Osteoporotic Fractures
A new study compared the fracture risks associated with NOACs vs. warfarin among AF patients on anticoagulant therapy. Which presents a better safety profile as it relates to bone health?European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 13, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Edoxaban Noninferior to Warfarin After Valve Surgery? Edoxaban Noninferior to Warfarin After Valve Surgery?
The first randomized trial comparing a DOAC with warfarin after bioprosthetic valve replacement surgery has been reported, but the question remains whether anticoagulation is needed at all.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 7, 2020 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news

Landmark Phase 3 VOYAGER PAD Study of XARELTO ® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefi...
Source: Johnson and Johnson - March 28, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

Stroke Risk in AF Patients on Rivaroxaban or Warfarin Stroke Risk in AF Patients on Rivaroxaban or Warfarin
This study compared the risk of stroke and all-cause mortality in patients taking rivaroxaban or warfarin for nonvalvular atrial fibrillation.Stroke (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 17, 2020 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

AUGUSTUS: Apixaban Bests Warfarin Despite Prior Stroke AUGUSTUS: Apixaban Bests Warfarin Despite Prior Stroke
In a prespecified secondary analysis of patients with a history of stroke, TIA, or thromboembolism, apixaban maintained an advantage over warfarin.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 10, 2020 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news

Minorities With ESRD and Afib Less Likely to Fill Prescriptions for Warfarin Minorities With ESRD and Afib Less Likely to Fill Prescriptions for Warfarin
Minority patients with end-stage renal disease (ESRD) and atrial fibrillation were less likely than whites to fill warfarin prescriptions, even though they were more likely to experience a stroke, researchers say.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - February 27, 2020 Category: Intensive Care Tags: Nephrology News Source Type: news

Secondary analysis confirms safety of blood thinning agent
(American Heart Association) The blood thinner apixaban, which treats and prevents blood clots in some people with irregular heart rhythm, is safe and effective in stroke patients. Apixaban is associated with less bleeding, death and hospitalization than warfarin. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 21, 2020 Category: International Medicine & Public Health Source Type: news

Warfarin Administration Time and Anticoagulation Stability Warfarin Administration Time and Anticoagulation Stability
Does it really matter if warfarin is taken in the evening or the morning?Annals of Family Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 11, 2020 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Compared With Warfarin, Non-Vitamin K Antagonist Oral Anticoagulants May Better Limit Risks to Bone Health
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - January 25, 2020 Category: Orthopaedics Tags: Trends and Innovations Source Type: news

Time of Day for Taking Warfarin Does Not Matter
WEDNESDAY, Jan. 22, 2020 -- Time of day for taking warfarin makes no difference on the drug's effectiveness, according to a study published in the January/February issue of the Annals of Family Medicine. Scott R. Garrison, M.D., Ph.D., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 22, 2020 Category: Pharmaceuticals Source Type: news

Do You Take Warfarin? Time of Day Might Not Matter
FRIDAY, Jan. 17, 2020 -- Patients taking the blood thinner warfarin have been told that it should be taken at night, but a new study found the time of day doesn't matter. " Whether warfarin is taken in the morning, or the evening, its therapeutic... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 17, 2020 Category: General Medicine Source Type: news

Fracture Risk Higher With Warfarin Vs DOACs Fracture Risk Higher With Warfarin Vs DOACs
Warfarin is associated with an increased risk of fractures compared with a direct oral anticoagulant (DOAC), a large real-world analysis has found.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - November 28, 2019 Category: Orthopaedics Tags: Cardiology News Source Type: news

Delayed intracranial hemorrhage in anticoagulated geriatric patients after ground level falls - Cocca AT, Privette A, Leon SM, Crookes BA, Hall G, Lena J, Eriksson EA.
BACKGROUND: The reported risk of delayed intracranial hemorrhage (ICH) in a trauma patient on warfarin is estimated to be between 0.6% and 6%. The risk of delayed ICH in trauma patients taking novel oral anticoagulants (NOACs) is not well-defined. ... (Source: SafetyLit)
Source: SafetyLit - November 23, 2019 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Risks After GI Bleeding in Anticoagulant, Antiplatelet Users Risks After GI Bleeding in Anticoagulant, Antiplatelet Users
When is it safe to resume aspirin or warfarin therapy after a major GI bleed?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 13, 2019 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Low-Intensity Warfarin Not Noninferior in Hip, Knee Surgery
TUESDAY, Nov. 5, 2019 -- Among older patients undergoing hip or knee replacement, low-intensity compared with standard-intensity warfarin prophylaxis did not meet the noninferiority criterion for the composite outcome of risk of venous... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 5, 2019 Category: Pharmaceuticals Source Type: news

DOACs Tied to Lower Fracture Risk vs Warfarin in AF DOACs Tied to Lower Fracture Risk vs Warfarin in AF
An observational study suggests all oral anticoagulants are not created equal: treatment with DOACs was associated with a lower risk for osteoporotic fractures than warfarin.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 22, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

Rivaroxaban Misfires in Antiphospholipid Syndrome Rivaroxaban Misfires in Antiphospholipid Syndrome
Rivaroxaban not only failed to show noninferiority to warfarin, but trended toward higher thrombosis risk in patients with APS.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 17, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

Rivaroxaban Cuts Recurrent Blood Clots in Obese Patients
Patients on rivaroxaban also have lower health care resource utilization than those on warfarin (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 30, 2019 Category: Cancer & Oncology Tags: Cardiology, Family Medicine, Internal Medicine, Oncology, Pharmacy, Journal, Source Type: news